Literature DB >> 60621

Host responses to hepatitis-B infection in patients with primary hepatic carcinoma and their families. A case/control study in Senegal, West Africa.

B Larouze, G Saimot, E D Lustbader, W T London, B G Werner, M Payet.   

Abstract

A case/control study of patients with primary hepatic carcinoma (P.H.C.) and their families was carried out in Dakar, Senegal. 28 P.H.C. cases were matched by age,sex, and ethnic group with 28 controls. Serum was collected from cases, controls, parents (28 mothers, 27 fathers) of cases, parents of controls, 71 siblings of cases, and 58 siblings of controls. Assays of their sera for hepatitis-B surface antigen (HBsAg), antibody to HBsAg (anti-HBs) and antibody to hepatitis-B core antigen (anti-HBc) produced the following results. (1) Nearly all P.H.C. cases (97%) and controls (93%) had some evidence of infection with hepatitis-B virus (H.B.V.), but the cases were more likely to be anti-HBc(+) and less likely to be anti-HBs(+) than the controls. (2) Most of the mothers of the cases were HBsAg(+) (71%), whereas only 14% of the mothers of controls were HBsAg(+). Lover titres of anti-HBs were less common in the mothers of the cases. (3) None of 27 fathers of cases had detectable anti-HBs, but 13 (48%) of the fathers of controls were anti-HBs(+). (4) Siblings of the P.H.C. cases were more likely to have anti-HBs than either their sibs with P.H.C. or the sibs of the controls. However, sibs of P.H.C. cases had lower titres of anti-HBs than the sibs of the controls. These data are consistent with the hypothesis that the P.H.C. cases were infected with H.B.V. by their mothers and that there was an environmental factor which affected the immunological response of all family members to H.B.V. Infection with H.B.V. and the mode of response to that infection among members of families appear to be major factors in the aetiology of P.H.C. in West Africa.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 60621     DOI: 10.1016/s0140-6736(76)91792-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  17 in total

Review 1.  Hepatocellular carcinoma. A worldwide problem and the major risk factors.

Authors:  R G Simonetti; C Cammà; F Fiorello; F Politi; G D'Amico; L Pagliaro
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

2.  Natural killer activity in patients with chronic hepatitis treated with OK432, interferon, adenine arabinoside and glycyrrhizin.

Authors:  T Wada; T Arima; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1987-06

3.  Hepatitis B virus antigens in primary hepatic carcinoma: immunofluorescent techniques on fixed liver tissue.

Authors:  A Trevisan; G Realdi; C Losi; V Ninfo; M Rugge; L Rampinelli
Journal:  J Clin Pathol       Date:  1978-12       Impact factor: 3.411

Review 4.  Beasley's 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention.

Authors:  Jill Koshiol; Zhiwei Liu; Thomas R O'Brien; Allan Hildesheim
Journal:  Cancer Epidemiol       Date:  2018-02-13       Impact factor: 2.984

5.  Hepatoma.

Authors: 
Journal:  West J Med       Date:  1980-06

6.  Hepatitis B virus DNA in human hepatocellular carcinoma: is the integration of hepatitis B virus DNA really carcinogenic?

Authors:  H Hada; T Arima; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1986-12

Review 7.  The global epidemiology of hepatocellular carcinoma: present and future.

Authors:  Katherine A McGlynn; W Thomas London
Journal:  Clin Liver Dis       Date:  2011-05       Impact factor: 6.126

Review 8.  Hepatitis B in pregnancy.

Authors:  J A Arevalo
Journal:  West J Med       Date:  1989-06

9.  In vitro and in vivo cytotoxic activity of native and ricin conjugated monoclonal antibodies to HBs antigen for Alexander primary liver cell carcinoma cells and tumours.

Authors:  J M Oladapo; A H Goodall; R de Koning; J Parmar; D Brown; H C Thomas
Journal:  Gut       Date:  1984-06       Impact factor: 23.059

Review 10.  Hepatitis B virus infection and primary hepatocellular carcinoma.

Authors:  M Feitelson
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.